title: [Patients with headache and medication abuse. Indicators of response to ambulatory treatment].
abstract: BACKGROUND
  Patients with headache and medication abuse (HMA) are difficult to treat, have a greater tendency towards chronification and a poorer quality of life than those with other types of headache. AIM. To evaluate the indicators showing that these patients are responding to ambulatory treatment.
  
  
  METHODS
  From a series of patients with migraine, we selected those who satisfied HMA criteria according to the appendix of the 2006 International Classification of the Headache Disease (ICHD-2) and who had never previously undergone treatment. As outpatients, they were advised to stop taking the drug that they were abusing. The treatment of their seizures was adjusted with the most efficient drugs and preventive treatment was started from the outset with topiramate or flunarizine. Patients were grouped according to whether they continued with HMA or not. Comparisons were made between the number of days with headache during the previous month and after four months of treatment and the persistence of abuse.
  
  
  RESULTS
  HMA criteria were met by 178 patients (mean age 40.9; 88.7% females). Results showed that 68.5% (122 patients) responded and no longer met HMA criteria after treatment. The treatment used for their seizures (triptans, nonsteroidal antiinflammatory drugs, analgesics) and preventive treatment (topiramate or flunarizine) were similar in both groups. The average number of days with headache prior to treatment was 18.52 in the group that responded and 20.87 (p = 0.0263) in the group that did not respond to treatment. In the group of responders 7.3% dropped out of preventive treatment compared with 35% (p = 0.0001) in the group of non-responders.
  
  
  CONCLUSIONS
  A higher number of days with headache during the previous month and withdrawing from preventive treatment were indicators of a bad progression.
authors.affiliation: Hospital Universitario Miguel Servet, Zaragoza, España. gracia.naya@meditex.es
authors.forename: M
authors.initials: M
authors.lastname: Gracia-Naya
authors.forename: S
authors.initials: S
authors.lastname: Sánchez-Valiente
authors.forename: A M
authors.initials: AM
authors.lastname: Latorre-Jiménez
authors.forename: C
authors.initials: C
authors.lastname: Ríos-Gómez
authors.forename: S
authors.initials: S
authors.lastname: Santos-Lasaosa
authors.forename: J A
authors.initials: JA
authors.lastname: Mauri-Llerda
authors.forename: M J
authors.initials: MJ
authors.lastname: García-Gomara
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D005260:Female; D006261:Headache / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000139:chemically induced* / Q000188:drug therapy*; D012651:Self Medication / Q000009:adverse effects*; D016896:Treatment Outcome